Jaguar Health (JAGX) Set to Announce Earnings on Monday

Jaguar Health (NASDAQ:JAGX) is scheduled to be posting its quarterly earnings results before the market opens on Monday, April 1st.

Jaguar Health Price Performance

NASDAQ:JAGX opened at $0.07 on Thursday. The stock has a 50-day moving average price of $0.08 and a two-hundred day moving average price of $0.20. Jaguar Health has a 1 year low of $0.05 and a 1 year high of $1.22. The company has a debt-to-equity ratio of 22.00, a current ratio of 1.77 and a quick ratio of 1.10.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Jaguar Health in a report on Thursday, March 21st. They issued a “sell” rating for the company.

Hedge Funds Weigh In On Jaguar Health

A number of large investors have recently added to or reduced their stakes in JAGX. Bank of New York Mellon Corp grew its stake in shares of Jaguar Health by 507.3% during the 1st quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 141,796 shares in the last quarter. Citigroup Inc. bought a new position in Jaguar Health in the first quarter valued at $34,000. Renaissance Technologies LLC acquired a new stake in Jaguar Health in the 1st quarter valued at $1,079,000. Goldman Sachs Group Inc. lifted its position in Jaguar Health by 153.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company’s stock worth $39,000 after buying an additional 33,148 shares in the last quarter. Finally, Virtu Financial LLC boosted its stake in shares of Jaguar Health by 76.1% during the 1st quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock worth $162,000 after buying an additional 99,073 shares during the last quarter. Institutional investors own 12.04% of the company’s stock.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.